Does NAD+ Actually Work? What Five Human Trials Reveal

Somewhere between the first longevity podcast and the fourth supplement subscription, a reasonable question gets buried: does NAD+ actually work?

It is a harder question than it sounds, because it hides two different questions inside one. The first is whether NAD+ matters to human biology, and that one is settled. NAD+ is a coenzyme your cells cannot run without, and its decline with age is one of the better documented facts in metabolic research. The second question is the one people actually care about at 45, standing in the kitchen at 3pm wondering why the afternoon feels like wading through wet sand: if I raise my NAD+, will anything in my life change?

Over the past four years, researchers have run real randomized trials to answer exactly that. Not mouse studies, not cell cultures, but double-blinded human trials in Parkinson's disease, mild cognitive impairment, peripheral artery disease, chronic obstructive pulmonary disease and chronic kidney disease. Read together, they tell a more interesting story than either the supplement industry or its critics want to admit.

What NAD+ Is Doing While You Read This

Nicotinamide adenine dinucleotide sits at the center of energy metabolism. Every time a cell converts food into usable ATP, NAD+ shuttles electrons through the process. It is also the required substrate for two families of enzymes tied closely to aging biology: the sirtuins, which regulate how genes are switched on and off, and the PARPs, which repair damaged DNA.

That dual role is why NAD+ became a longevity obsession. Your cells spend it on energy production and on repair, and when supply tightens, those two priorities start competing. Tissue levels fall measurably with age, and they fall further under inflammation, poor sleep, alcohol and chronic metabolic stress.

So the biology is sound. The open question has always been whether topping up the supply produces anything a person can feel.

Trial One: Getting NAD+ Into the Organ That Matters

The most methodologically interesting trial in this literature is the NADPARK study, a double-blinded phase I trial of oral nicotinamide riboside in people with Parkinson's disease, published in Cell Metabolism [1].

What makes it valuable is not the disease it studied but what it measured. Nearly every NAD+ study before it measured blood. NADPARK used brain imaging to ask whether oral supplementation raises NAD levels inside the living human brain and whether cerebral metabolism shifts in response. That is a genuinely difficult measurement, and asking it at all moved the field forward.

The design was explicitly built to establish whether NAD replenishment therapy, taken orally, is safe and whether it augments cerebral NAD levels [1]. Safety at the doses studied looked reassuring. The deeper lesson is one of plumbing: a molecule raising a number in your bloodstream is not the same as that molecule reaching the tissue you are worried about.

Trial Two: Does NAD+ Actually Work for Memory and Thinking?

This is where the honest answer gets uncomfortable. A randomized placebo-controlled trial in GeroScience gave nicotinamide riboside to older adults living with mild cognitive impairment, the stage where memory slips are measurable but daily independence is intact [2].

The biochemistry behaved exactly as predicted.

"NR significantly increased blood NAD+ concentrations in older adults" [2]

Notice what the paper's own summary leads with. It leads with the biomarker, not the cognition. That is not a scandal, it is how early trials in this space usually read. Cognitive endpoints are noisy, the samples are small, the follow-up windows are short, and a few months of supplementation in an aging brain is a modest intervention against decades of accumulated change.

The useful takeaway is calibration. Studies suggest NAD+ precursors reliably move the molecule. Whether they move memory in people already experiencing cognitive decline is a much larger, longer and more expensive question that has not been answered yet.

Trials Three and Four: Walking, Breathing and Harder Endpoints

Two 2024 trials went after outcomes you cannot fake on a questionnaire.

The NICE trial, published in Nature Communications, tested oral nicotinamide riboside in people with lower extremity peripheral artery disease, a population defined by poor walking performance alongside increased oxidative stress and impaired mitochondrial activity [3]. Walking capacity is a brutally honest endpoint. Either you cover more ground or you do not.

The second, published in Nature Aging, treated 40 patients with stable COPD with nicotinamide riboside for six weeks and followed them twelve weeks later, looking at airway inflammation and reporting changes in secondary inflammatory outcomes [4]. Six weeks is short. Forty patients is small. But the trial asked whether an NAD+ precursor changes an inflammatory process in sick human lungs, which is a far more demanding question than whether it changes a blood value.

Both studies belong to a pattern worth noticing: when researchers test NAD+ precursors against hard functional endpoints in people with established disease, the effects are modest and inconsistent. When they test against biochemical markers, the effects are robust. Any honest answer to whether NAD+ works has to hold both of those facts at once.

Trial Five: When NAD+ Is Not Working Alone

A randomized, placebo-controlled, double-blind crossover trial in JCI Insight took a different approach, pairing coenzyme Q10 with nicotinamide riboside to test their impact on exercise tolerance and metabolic profile in patients with chronic kidney disease [5].

The combination approach reflects where the science is drifting. Mitochondrial function is not a single dial. It depends on electron carriers, antioxidant capacity, membrane integrity and substrate availability all at once, which is why single-nutrient trials often underperform the mechanism that inspired them.

The same logic shows up in the glutathione literature. A randomized clinical trial in older adults found that supplying glycine and N-acetylcysteine together improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function and multiple hallmarks of aging [6]. The intervention that moved the needle was the one that addressed the whole pathway rather than one node in it.

The Gap Between a Biomarker and a Monday Morning

Here is the uncomfortable centerpiece of this entire literature. Raising NAD+ in blood is close to a solved problem. Proving that the raised number translates into a better Monday morning is not.

Part of this is study design. Clinical trials recruit people with diagnosed disease, because that is how trials get funded and approved. A 52-year-old who sleeps badly, trains four times a week and feels flat by mid-afternoon is not in any of these studies. Her physiology has far more headroom than a patient with advanced peripheral artery disease, and whether that headroom makes her more responsive or simply harder to measure is genuinely unknown.

Part of it is route. Nearly every trial above used oral nicotinamide riboside, because oral dosing is cheap to run and easy to blind. Injectable NAD+, which bypasses first-pass metabolism entirely, has almost no comparable randomized data behind it. Patients report faster and more noticeable effects, and the pharmacology makes that plausible, but plausible is not proven. Anyone claiming otherwise is selling something.

And part of it is time. Aging is a multi-decade process. Six-week trials are a reasonable way to test safety and biochemistry. They are a poor way to test whether something slows a process that takes thirty years.

So What Should You Do With Any of This?

If you are 40 to 55, tired in a way sleep does not fix, and looking at NAD+ therapy, three conclusions follow from the evidence rather than the marketing.

First, treat NAD+ as support for the machinery of energy production, not as a stimulant and certainly not as a cure. The research consistently places it upstream of how cells make and repair, which is a slower and quieter kind of benefit than a double espresso.

Second, fix the inputs that drain NAD+ before you spend money replacing it. Short sleep, heavy alcohol, chronic inflammation and sedentary weeks all increase demand on the same pool. No protocol outruns a 5-hour sleep average.

Third, if you do pursue therapy, do it with a physician who will establish a baseline, pick a defined trial period and evaluate honestly at the end. A supervised program such as the NAD+ injection protocol at RenuviaRX exists for exactly that reason, with a licensed clinician reviewing your history before anything is prescribed. The point of medical supervision is not reassurance, it is having someone qualified to tell you when something is not working.

Reading the Evidence Like an Adult

So, does NAD+ actually work? The most defensible answer available today is this: NAD+ precursors reliably do what they claim at the biochemical level, they appear safe in the populations studied so far, and their effect on how a healthy midlife adult feels and performs remains an open question that current trials were not designed to answer.

That is a less thrilling headline than either side of the debate prefers. It is also the only version supported by the data. The sensible move at 45 is not blind faith or blanket dismissal, but a structured trial with a clinician, clear expectations and a willingness to stop if nothing changes. If you want to find out where you actually stand, a medical intake review is the place that conversation starts.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism. 2022;34(3):396-407.e6. doi:10.1016/j.cmet.2022.02.001
2. Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, Brenner C, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46(1):665-682. doi:10.1007/s11357-023-00999-9
3. McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. 2024;15(1):5046. doi:10.1038/s41467-024-49092-5
4. Norheim KL, Ben Ezra M, Heckenbach I, Andreasson LM, Eriksen LL, Dyhre-Petersen N, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nature Aging. 2024;4(12):1772-1781. doi:10.1038/s43587-024-00758-1
5. Ahmadi A, Begue G, Valencia AP, Norman JE, Lidgard B, Bennett BJ, et al. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight. 2023;8(11):e167274. doi:10.1172/jci.insight.167274
6. Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. The Journals of Gerontology: Series A. 2023;78(1):75-89. doi:10.1093/gerona/glac135